1-5 of 5
Eric Haura
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

Christopher T. Letson, Maria E. Balasis, Hannah Newman, Moritz Binder, Alexis Vedder, Fumi Kinose, Markus Ball, Traci Kruer, Ariel Quintana, Terra L. Lasho, Christy M. Finke, Luciana L. Almada, Jennifer M. Grants, Guolin Zhang, Martin E. Fernandez-Zapico, Alexandre Gaspar-Maia, Jeffrey Lancet, Rami Komrokji, Eric Haura, David A. Sallman, Gary W. Reuther, Aly Karsan, Uwe Rix, Mrinal M. Patnaik, Eric Padron
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2919–2932.
https://doi.org/10.1158/1078-0432.CCR-22-3929
Published: 01 August 2023
View article titled, Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
Open the PDF for Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML in another window
Includes: Supplementary data
Journal Articles

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Dara L. Aisner, Lynette M. Sholl, Lynne D. Berry, Michael R. Rossi, Heidi Chen, Junya Fujimoto, Andre L. Moreira, Suresh S. Ramalingam, Liza C. Villaruz, Gregory A. Otterson, Eric Haura, Katerina Politi, Bonnie Glisson, Jeremy Cetnar, Edward B. Garon, Joan Schiller, Saiama N. Waqar, Lecia V. Sequist, Julie Brahmer, Yu Shyr, Kelly Kugler, Ignacio I. Wistuba, Bruce E. Johnson, John D. Minna, Mark G. Kris, Paul A. Bunn, David J. Kwiatkowski
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (5): 1038–1047.
https://doi.org/10.1158/1078-0432.CCR-17-2289
Published: 28 February 2018
View article titled, The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Open the PDF for The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2) in another window
Includes: Supplementary data
Journal Articles

Evaluation of targeted therapeutics in cell lines and patient samples by quantifying signal transduction and protein levels

David Voehringer, Debabrita Deb-Basu, Alice Fan, Dean Felsher, Eric Haura
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15_Supplement): A7.
Published: 15 August 2014
View article titled, Evaluation of targeted therapeutics in cell lines and patient samples by quantifying signal transduction and protein levels
Journal Articles

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors

Jhanelle E. Gray, Eric Haura, Alberto Chiappori, Tawee Tanvetyanon, Charles C. Williams, Mary Pinder-Schenck, Julie A. Kish, Jenny Kreahling, Richard Lush, Anthony Neuger, Leticia Tetteh, Angela Akar, Xiuhua Zhao, Michael J. Schell, Gerold Bepler, Soner Altiok
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (6): 1644–1655.
https://doi.org/10.1158/1078-0432.CCR-13-2235
Published: 13 March 2014
View article titled, A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
Open the PDF for A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors in another window
Journal Articles

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori, Eric Haura, Francisco A. Rodriguez, David Boulware, Rachna Kapoor, Anthony M. Neuger, Richard Lush, Barbara Padilla, Michelle Burton, Charles Williams, George Simon, Scott Antonia, Daniel M. Sullivan, Gerold Bepler
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1464–1469.
https://doi.org/10.1158/1078-0432.CCR-07-1508
Published: 03 March 2008
View article titled, Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer in another window